ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

The existing work examined the potential of employing ARV-825 and ABBV-744 to boost the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in each p53 wild-variety (WT) breast tumor cells As well as in cells missing practical p53 either on your own or in combination with tamoxifen, when the effectiveness of ABBV